Inventor · disambiguated record
Gerd Ritter
Also filed as: JUNGBLUTH ACHIM · RITTER GERD · RITTER GERD J
60 granted patents·30 pending applications·621 citations·filing 1988–2025
99Inventor score
Files withAGENUS INC41LUDWIG INST CANCER RES20LUDWIG INST FOR CANCER RES LTD9RITTER GERD5SLOAN KETTERING INST CANCER3
Top patents by PatentIndex Score
90 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0297US10836830B2Antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Nov 17, 2020·12 cites·45 claims
- 0396US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0496US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0596US10280226B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted May 7, 2019·17 cites·30 claims
- 0696US10155818B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2015·Granted Dec 18, 2018·17 cites·4 claims
- 0795US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 0895US7589180B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Sep 15, 2009·70 cites·4 claims
- 0994US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 1093US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 1192US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 1292US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 1392US8603474B2Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapyRITTER GERD·Filed 2009·Granted Dec 10, 2013·27 cites·11 claims
- 1489US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 1589US6342587B1A33 antigen specific immunoglobulin products and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Jan 29, 2002·93 cites·15 claims
- 1688US10800849B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Oct 13, 2020·2 cites·26 claims
- 1787US10577426B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Mar 3, 2020·3 cites·21 claims
- 1887US9072798B2Specific binding proteins and uses thereofRITTER GERD·Filed 2010·Granted Jul 7, 2015·8 cites·25 claims
- 1987US6652853B2Method for treating cancer using A33 specific antibodies and chemotherapeutic agentsLUDWIG INST CANCER RES·Filed 2001·Granted Nov 25, 2003·28 cites·28 claims
- 2087US6346249B1Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin productsLUDWIG INST CANCER RES·Filed 2000·Granted Feb 12, 2002·13 cites·19 claims
- 2186US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 2285US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 2385US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 2485US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 2585US5712369AIsolated protein which binds to A33 antibody, and peptides corresponding to portions of the proteinLUDWIG INST CANCER RES·Filed 1996·Granted Jan 27, 1998·63 cites·7 claims
- 2684US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 2784US11447557B2Antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Sep 20, 2022·3 cites·46 claims
- 2884US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 2984US10829559B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Nov 10, 2020·1 cites·8 claims
- 3084US9562102B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2012·Granted Feb 7, 2017·3 cites·2 claims
- 3184US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3284US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 3384US2024117073A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 3482US5102663AVaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3SLOAN KETTERING INSTUTUTE FOR·Filed 1988·Granted Apr 7, 1992·50 cites·22 claims
- 3582US2023039577A1Anti-gitr antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3680US11359028B2Anti-OX40 antibodies and anti-GITR antibodiesAGENUS INC·Filed 2019·Granted Jun 14, 2022·1 cites·16 claims
- 3780US2023406946A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3880US2023399413A1Antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 3979US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 4079US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 4178US9045533B2Membrane transporter NaPi2b (SCL34A2) epitope antibodiesRITTER GERD·Filed 2013·Granted Jun 2, 2015·3 cites·8 claims
- 4277US8357373B2Methods for stimulating an immune response using bacterial antigen delivery systemLUDWIG INST CANCER RES·Filed 2006·Granted Jan 22, 2013·1 cites·28 claims
- 4376US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 4475US11897962B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 13, 2024·0 cites·11 claims
- 4575US5851526AMethods of treating colon cancer utilizing tumor-specific antibodiesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 22, 1998·36 cites·11 claims
- 4675US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 4774US6291235B1Isolated nucleic acid which encodes protein which binds to A33 antibodyLUDWIG INST CANCER RES·Filed 1996·Granted Sep 18, 2001·24 cites·6 claims
- 4873US11401335B2Anti-GITR antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 2, 2022·0 cites·16 claims
- 4973US2022389107A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 5073US2022380479A1Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 90 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gerd Ritter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →